

Researchers take another big step toward HIV cure

September 18 2023, by Vibe Bregendahl Noordeloos

Screening							
	3BNC117		10-1074				
No. of seqs.	Pheno- Sense	genotype	Pheno- Sense	<i>env</i> genotype		 ✓ Placebo for 3BNC117 (i.v.) ✓ Placebo for 10-1074 (i.v.) 	
	0.75		0.17		ID112 -		
	0.15		0.13		ID112		
	0.37		0.08		ID304 -		
39		97%		97%	ID817 -		
18	3.69	100%	0.88	100%	ID141 -	ART Resumed	
27	0.16	100%	0.51	100%	ID502 -	Resumed	
29		100%		100%	ID802 -		
19	0.65	100%	0.12	100%	ID104 -		
25	3.59	100%	0.16	100%	ID313 -		
22		95%		100%	ID411 -		
22	0.81	9%	0.69	100%	ID501 -		
	0.86		0.13		ID816 -		
24	0.38	13%	0.18	100%	ID134 -		
	0.58		0.15		ID603 -		
	0.61		0.76		ID814 -		
31	0.46	97%	0.12	100%	ID205 -	· · · · · · · · · · · · · · · · · · ·	
					ID614 -		
					ID808 -		
24	0.78	100%	0.13	100%	ID202 -		
					0	2 4 6 8 10 12 14 16 18 20 22 24 2 Time (weeks after ART interuption)	
	Nonogr	am Pheno	Sense			env genotype Placebo/placebo	
		NC117	10-1074			3BNC117 and 10-1074 Lefitolimod/placebo	
_	ive IC90 <		IC90 < 2.0 μg/			nces are sensitive to the respective bNAb No attempt to amplify	
Resista	ant (C90 2	:1.5 μg/ml	IC90 ≥2.0 µg/	m) ≤90%	of known sequ	uences are sensitive to the respective bNAb Failure	

bNAb sensitivity at screening for the placebo/placebo and lefitolimod/placebo



groups. bNAb sensitivity was primarily analyzed using the PhenoSense Monoclonal Antibody Assay with predefined IC90 thresholds for 3BNC117 (

Citation: Researchers take another big step toward HIV cure (2023, September 18) retrieved 13 May 2024 from <u>https://medicalxpress.com/news/2023-09-big-hiv.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.